We are live on ! Find out more

Novo Nordisk

NVO

Market cap $178B

40.45 USD

+0.45

1.13%

At close Updated Nov 2, 4:00 PM EST

Pre-market

After hours

40.41

-0.04

0.1%

1 day

1.13%

5 days

4.85%

1 month

8.39%

3 months

-14.1%

6 months

-8.88%

Year to date

-22.79%

1 year

-17.63%

5 years

-26.49%

10 years

129.57%

About: With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Employees: 69,500

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 48.9%

Neutral 25.1%

Negative 26%

Zacks Investment Research

Novo Before Q3 Earnings: How Should Investors Play the Stock?

NVO faces intensifying GLP-1 competition, earnings cuts and pricing pressure, challenging its growth outlook ahead of Q3 results.

Novo Before Q3 Earnings: How Should Investors Play the Stock?

The Motley Fool

Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?

Novo Nordisk is one of two leading GLP-1 producers. The company is cutting prices on its GLP-1 drugs as it shifts toward a volume-driven model.

Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?

Zacks Investment Research

Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock

The Motley Fool

Novo Has Big Plans for 2030. Should You Buy the Stock Now?

Novo plans to expand its lineup and pipeline by 2030, while serving far more patients. The company seems well positioned to accomplish many of its goals.

Novo Has Big Plans for 2030. Should You Buy the Stock Now?

24/7 Wall Street

Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases

Eli Lilly (NYSE:LLY | LLY Price Prediction) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the glucagon-like peptide-1 (GLP-1) group is barely moving.

Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases

24/7 Wall Street

16% of Employers Are Thinking About Cutting Weight-Loss Drug Coverage

Employers are quietly reconsidering who foots the bill for GLP-1 weight-loss drugs, and the fallout hits Eli Lilly and Novo Nordisk very differently heading into earnings week.

16% of Employers Are Thinking About Cutting Weight-Loss Drug Coverage

Investors Business Daily

Lilly's Reta Trounces Novo Powerhouse In Head-To-Head Test

Eli Lilly's next-generation weight-loss drug, retatrutide, trounced Novo's Ozempic in a head-to-head study, the company said Wednesday.

Lilly's Reta Trounces Novo Powerhouse In Head-To-Head Test

Zacks Investment Research

Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors

In the latest trading session, Novo Nordisk (NVO) closed at $38.7, marking a -1.11% move from the previous day.

Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors

Novo Nordisk Vs. Eli Lilly Q3 Preview: I'd (Now) Buy Both, But Lilly Is My Top Pick

Eli Lilly and Company has decisively outpaced Novo Nordisk A/S in the GLP-1/obesity/T2D market, now commanding a $1.21T valuation. NVO's share price has retraced all post-Wegovy gains; revenue growth is stagnant, but management's reset and pipeline strategy prompt a Buy upgrade. LLY's pipeline, momentum, and manufacturing strength support continued dominance, with the potential to surpass $100B in annual revenues as early as next year.

Novo Nordisk Vs. Eli Lilly Q3 Preview: I'd (Now) Buy Both, But Lilly Is My Top Pick

The Motley Fool

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?

Amgen maintains a robust presence in oncology and rare diseases with a 9.9% revenue growth rate in FY 2025. Novo Nordisk continues to dominate the global diabetes and obesity markets with a high net margin of 33.1%.

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?

See News Rankings

Price charts implemented using Lightweight Charts™